What does this research mean for the field?

The FDA has approved Idvynso (doravirine/islatravir) as the first once-daily, two-drug antiretroviral regimen that does not contain an INSTI or tenofovir for virologically suppressed adults with HIV-1. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review the FDA approval and therapeutic profile of the once-daily fixed-dose combination of doravirine and islatravir for HIV-1 maintenance therapy.

August 26, 2026The medical letter on drugs and therapeutics/The medical letter

Doravirine/Islatravir (Idvynso) for HIV

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Overview

Regulatory review reports approval of doravirine/islatravir for virologically suppressed adults with HIV-1, indicating an effective two-drug option free of integrase inhibitors or tenofovir.

Key Points

To review the FDA approval and therapeutic profile of the once-daily fixed-dose combination of doravirine and islatravir for HIV-1 maintenance therapy.
Evaluated the fixed-dose oral combination of doravirine (NNRTI) and islatravir (first-in-class NRTTI).
Assessed indication criteria: virologically suppressed adults with HIV-1 RNA <50 copies/mL on a stable regimen, without past virologic failure or doravirine-associated resistance mutations.
Idvynso represents the first two-drug HIV regimen that does not contain an integrase strand transfer inhibitor (INSTI) or tenofovir.
The regimen provides an alternative switch option utilizing islatravir's translocation inhibition mechanism paired with doravirine.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a8e9af2451774b83f3b35fc https://doi.org/10.58347/tml.2026.1762b

View Full Paper

Ask AI

Bookmark

August 26, 2026The medical letter on drugs and therapeutics/The medical letter

Doravirine/Islatravir (Idvynso) for HIV

View Full Paper

Ask AI

Bookmark

Discussion

Member takes

Overview

Regulatory review reports approval of doravirine/islatravir for virologically suppressed adults with HIV-1, indicating an effective two-drug option free of integrase inhibitors or tenofovir.

Key Points

To review the FDA approval and therapeutic profile of the once-daily fixed-dose combination of doravirine and islatravir for HIV-1 maintenance therapy.
Evaluated the fixed-dose oral combination of doravirine (NNRTI) and islatravir (first-in-class NRTTI).
Assessed indication criteria: virologically suppressed adults with HIV-1 RNA <50 copies/mL on a stable regimen, without past virologic failure or doravirine-associated resistance mutations.
Idvynso represents the first two-drug HIV regimen that does not contain an integrase strand transfer inhibitor (INSTI) or tenofovir.
The regimen provides an alternative switch option utilizing islatravir's translocation inhibition mechanism paired with doravirine.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a8e9af2451774b83f3b35fc https://doi.org/10.58347/tml.2026.1762b

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark